Results

Zacks Small Cap Research – CTSO: CytoSorbents Reports 4th quarter and 2024 Financial Results Which Showed Impressive Product Revenue Growth That Exceeded Our Expectations. – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT Update on the DrugSorb-ATR Regulatory Process Management reiterated that their De Novo DrugSorb-ATR submission continued to be in interactive review with FDA, that their Medical Device License application to Health Canada was in advanced review, and that they continue to expect regulatory decisions in … Read more

Zacks Small Cap Research – LTRN: 2024 Financial Results – Go Health Pro

by
Zacks Small Cap Research – LTRN: 2024 Financial Results – Go Health Pro

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Lantern Pharma, Inc (NASDAQ:LTRN) reports 2024 results highlighting several achievements including progress on its HARMONIC, LP-184 and LP-284 trials, a portfolio of expedited designations in multiple indications and advances in the RADR platform with modules that offer predictive algorithms for blood brain barrier (BBB) … Read more

Zacks Small Cap Research – VIOT: A deep value growth story delivers solid results. Increasing our estimates and valuation target to $4.50 – Go Health Pro

by

By Brian Lantier, CFA NASDAQ:VIOT READ THE FULL VIOT RESEARCH REPORT On Tuesday, March 25th, Viomi Technology (NASDAQ:VIOT) released its second half and full year for 2024. As a result of the company’s divestiture of its IoT business in August 2024, the company is a pure-play home water systems and home appliance company. Importantly, the … Read more

Zacks Small Cap Research – SDOT: Sadot Group Reports 2024 Financial Results Which Showed the First Full Year Positive Net Income in the Company’s History – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:SDOT READ THE FULL SDOT RESEARCH REPORT 4th Quarter and Full Year 2024 Financial Results On March 11, 2025, Sadot Group (NASDAQ:SDOT) reported 4th quarter and full year 2024 results which showed continued strength in the commodity trading business. In the latest filings, the restaurant operations have been reported as discontinued … Read more

Zacks Small Cap Research – MGRM: Monogram Technologies Reports 4th Quarter and Full Year 2024 Results – Go Health Pro

by
Zacks Small Cap Research – MGRM: Monogram Technologies Reports 4th Quarter and Full Year 2024 Results – Go Health Pro

By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT 4th Quarter and Full Year 2024 Financial Results Monogram (NASDAQ:MGRM) reported 4th quarter and full year 2024 financial results on March 12th which were largely in line with our expectations. Research and development expenses for 2024 were $8.8 million compared to $10.6 million in … Read more